Dr Antony Cooper

Wyse RK; Cooper AA; Stott SRW, 2022, 'Chapter 3: The Role of Clinical Medicine', in Drug Repurposing, pp. 24 - 51, http://dx.doi.org/10.1039/9781839163401-00024

Bournazos AM; Riley LG; Bommireddipalli S; Ades L; Akesson LS; Al-Shinnag M; Alexander SI; Archibald AD; Balasubramaniam S; Berman Y; Beshay V; Boggs K; Bojadzieva J; Brown NJ; Bryen SJ; Buckley MF; Chong B; Davis MR; Dawes R; Delatycki M; Donaldson L; Downie L; Edwards C; Edwards M; Engel A; Ewans LJ; Faiz F; Fennell A; Field M; Freckmann ML; Gallacher L; Gear R; Goel H; Goh S; Goodwin L; Hanna B; Harraway J; Higgins M; Ho G; Hopper BK; Horton AE; Hunter MF; Huq AJ; Josephi-Taylor S; Joshi H; Kirk E; Krzesinski E; Kumar KR; Lemckert F; Leventer RJ; Lindsey-Temple SE; Lunke S; Ma A; Macaskill S; Mallawaarachchi A; Marty M; Marum JE; McCarthy HJ; Menezes MP; McLean A; Milnes D; Mohammad S; Mowat D; Niaz A; Palmer EE; Patel C; Patel SG; Phelan D; Pinner JR; Rajagopalan S; Regan M; Rodgers J; Rodrigues M; Roxburgh RH; Sachdev R; Roscioli T; Samarasekera R; Sandaradura SA; Savva E; Schindler T; Shah M; Sinnerbrink IB; Smith JM; Smith RJ; Springer A; Stark Z; Strom SP; Sue CM; Tan K; Tan TY; Tantsis E; Tchan MC; Thompson BA; Trainer AH; van Spaendonck-Zwarts K; Walsh R; Warwick L; White S; White SM; Williams MG, 2022, 'Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants', Genetics in Medicine, vol. 24, pp. 130 - 145, http://dx.doi.org/10.1016/j.gim.2021.09.001

Farrow SL; Cooper AA; O’Sullivan JM, 2022, 'Redefining the hypotheses driving Parkinson’s diseases research', npj Parkinson's Disease, vol. 8, http://dx.doi.org/10.1038/s41531-022-00307-w

Farrow SL; Schierding W; Gokuladhas S; Golovina E; Fadason T; Cooper AA; O'Sullivan JM, 2022, 'Establishing gene regulatory networks from Parkinson's disease risk loci', Brain, vol. 145, pp. 2422 - 2435, http://dx.doi.org/10.1093/brain/awac022

Ho D; Schierding W; Farrow SL; Cooper AA; Kempa-Liehr AW; O’Sullivan JM, 2022, 'Machine Learning Identifies Six Genetic Variants and Alterations in the Heart Atrial Appendage as Key Contributors to PD Risk Predictivity', Frontiers in Genetics, vol. 12, http://dx.doi.org/10.3389/fgene.2021.785436

Huang Y; Wei J; Cooper A; Morris MJ, 2022, 'Parkinson's disease: From genetics to molecular dysfunction and targeted therapeutic approaches', Genes and Diseases, http://dx.doi.org/10.1016/j.gendis.2021.12.015

Lau D; Magnan C; Hill K; Cooper A; Gambin Y; Sierecki E, 2022, 'Single Molecule Fingerprinting Reveals Different Amplification Properties of α-Synuclein Oligomers and Preformed Fibrils in Seeding Assay', ACS Chemical Neuroscience, vol. 13, pp. 883 - 896, http://dx.doi.org/10.1021/acschemneuro.1c00553

Zhang JD; Le MN; Hill KJ; Cooper AA; Stuetz RM; Donald WA, 2022, 'Identifying robust and reliable volatile organic compounds in human sebum for biomarker discovery', Analytica Chimica Acta, vol. 1233, pp. 340506 - 340506, http://dx.doi.org/10.1016/j.aca.2022.340506

Guennewig B; Lim J; Marshall L; McCorkindale AN; Paasila PJ; Patrick E; Kril JJ; Halliday GM; Cooper AA; Sutherland GT, 2021, 'Author Correction: Defining early changes in Alzheimer’s disease from RNA sequencing of brain regions differentially affected by pathology (Scientific Reports, (2021), 11, 1, (4865), 10.1038/s41598-021-83872-z)', Scientific Reports, vol. 11, http://dx.doi.org/10.1038/s41598-021-97076-y

Guennewig B; Lim J; Marshall L; McCorkindale AN; Paasila PJ; Patrick E; Kril JJ; Halliday GM; Cooper AA; Sutherland GT, 2021, 'Defining early changes in Alzheimer’s disease from RNA sequencing of brain regions differentially affected by pathology', Scientific Reports, vol. 11, pp. 4865, http://dx.doi.org/10.1038/s41598-021-83872-z

O'Sullivan JM; den Heijer JM; Groeneveld GJ; Cooper AA, 2021, 'Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup', Movement Disorders, vol. 36, pp. 1468 - 1470, http://dx.doi.org/10.1002/mds.28620

Schierding W; Farrow S; Fadason T; Graham OEE; Pitcher TL; Qubisi S; Davidson AJ; Perry JK; Anderson TJ; Kennedy MA; Cooper A; O'Sullivan JM, 2020, 'Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset', Movement Disorders, vol. 35, pp. 1346 - 1356, http://dx.doi.org/10.1002/mds.28144

Toma C; Shaw AD; Overs BJ; Mitchell PB; Schofield PR; Cooper AA; Fullerton JM, 2020, 'De Novo Gene Variants and Familial Bipolar Disorder', JAMA network open, vol. 3, pp. e203382, http://dx.doi.org/10.1001/jamanetworkopen.2020.3382

Montgomery MK; Osborne B; Brandon AE; O'Reilly L; Fiveash CE; Brown SHJ; Wilkins BP; Samsudeen A; Yu J; Devanapalli B; Hertzog A; Tolun AA; Kavanagh T; Cooper AA; Mitchell TW; Biden TJ; Smith NJ; Cooney GJ; Turner N, 2019, 'Regulation of mitochondrial metabolism in murine skeletal muscle by the medium-chain fatty acid receptor Gpr84', FASEB Journal, vol. 33, pp. 12264 - 12276, http://dx.doi.org/10.1096/fj.201900234R

Dong X; Liao Z; Gritsch D; Hadzhiev Y; Bai Y; Locascio JJ; Guennewig B; Liu G; Blauwendraat C; Wang T; Adler CH; Hedreen JC; Faull RLM; Frosch MP; Nelson PT; Rizzu P; Cooper AA; Heutink P; Beach TG; Mattick JS; Müller F; Scherzer CR, 2018, 'Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease', Nature Neuroscience, vol. 21, pp. 1482 - 1492, http://dx.doi.org/10.1038/s41593-018-0223-0

Murphy KE; Gysbers AM; Abbott SK; Spiro AS; Furuta A; Cooper A; Garner B; Kabuta T; Halliday GM, 2015, 'Lysosomal-associated membrane protein 2 isoforms are differentially affected in early Parkinson's disease', Movement Disorders, vol. 30, pp. 1639 - 1647, http://dx.doi.org/10.1002/mds.26141

Guennewig B; Cooper AA, 2014, 'The central role of noncoding RNA in the brain', International Review of Neurobiology, vol. 116, pp. 153 - 194, http://dx.doi.org/10.1016/B978-0-12-801105-8.00007-2

Kong SMY; Chan BKK; Park JS; Hill KJ; Aitken JB; Cottle L; Farghaian H; Cole AR; Lay PA; Sue CM; Cooper AA, 2014, 'Parkinson's disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes α-Synuclein externalization via exosomes', Human Molecular Genetics, vol. 23, pp. 2816 - 2833, http://dx.doi.org/10.1093/hmg/ddu099

Murphy KE; Cottle L; Gysbers AM; Cooper AA; Halliday GM, 2014, 'ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies', Acta Neuropathologica Communications, vol. 2, pp. 11, http://dx.doi.org/10.1186/2051-5960-1-11

Murphy KE; Gysbers AM; Abbott SK; Tayebi N; Kim WS; Sidransky E; Cooper A; Garner B; Halliday GM, 2014, 'Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease', Brain, vol. 137, pp. 834 - 848, http://dx.doi.org/10.1093/brain/awt367

Chesi A; Kilaru A; Fang X; Cooper A, 2012, 'The role of the Parkinson's disease gene PARK9 in essential cellular pathways and the manganese homeostasis network in yeast', PLoS One, vol. 7, pp. e34178, http://dx.doi.org/10.1371/journal.pone.0034178

Protter D; Lang C; Cooper A; Lang C, 2012, 'alphaSynuclein and mitochondrial dysfunction: A pathogenic partnership in Parkinson's Disease?', Parkinson's Disease, vol. 2012, pp. 829207, http://dx.doi.org/10.1155/2012/829207

Park JS; Mehta P; Cooper A; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM, 2011, 'Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism', Human Mutation, vol. 32, pp. 956 - 964, http://dx.doi.org/10.1002/humu.21527

Webber K; Cooper A; Kleiven H; Yip D; Goldstein D, 2011, 'Management of metastatic renal cell carcinoma in the era of targeted therapies', Internal Medicine Journal, vol. 41, pp. 594 - 605, http://dx.doi.org/10.1111/j.1445-5994.2011.02540.x

McConoughey S; Basso SJ; Nietsetskaya Z; Sleiman SF; Smirnova T; Langley B; Mahishi L; Cooper AJ; Antonyak MA; Cerione RA; Li B; Starkov A; Chaturvedi R; Beale M; Coppola G; Geschwind D; Ryu H; Li XR; Iismaa SE; Pallos J; Pasternack R; Hils M; Fan J; Raymond LA; Marsh JL; Thompson LM; Ratan R, 2010, 'Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease', EMBO Journal, vol. 2, pp. 349 - 370, http://dx.doi.org/10.1002/emmm.201000084

Su LJ; Auluck PK; Outeiro TF; Yeger-Lotem E; Kritzer J; Tardiff D; Strathearn K; Liu F; Cao S; Hamamichi S; Hill KJ; Caldwell K; Bell GW; Fraenkel E; Cooper A; Caldwell G; McCaffery J; Rochet J-C; Lindquist S, 2010, 'Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models', Disease Models and Mechanisms, vol. 3, pp. 194-208, http://dx.doi.org/10.1242/dmm.004267

Bunce M; Worthy T; Phillips M; Holdaway RN; Willerslev E; Haile J; Shapiro RP; Scofield RP; Drummond A; Kamp PJJ; Cooper A, 2009, 'The evolutionary history of the extinct ratite moa and New Zealand Neogene paleogeography.', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, pp. 20646 - 20651, http://dx.doi.org/10.1073/pnas.0906660106

Gitler A; Chesi A; Geddie M; Strathearn K; Hamamichi S; Caldwell K; Hill KJ; Caldwell G; Cooper A; Rochet J; Lindquist S, 2009, 'Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity', Nature Genetics, vol. 41, pp. 308 - 315, http://dx.doi.org/10.1038/ng.300

Gitler AD; Chesi A; Geddie ML; Strathearn KE; Hamamichi S; Hill KJ; Caldwell KA; Caldwell GA; Cooper AA; Rochet JC; Lindquist S, 2009, 'α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity', Nature Genetics, vol. 41, pp. 308 - 315, http://dx.doi.org/10.1038/ng.300

Zhao JT; Hill A; Varghese A; Cooper A; Swan H; Laitinen-Forsblom P; Rees M; Skinner J; Campbell TJ; Vandenberg JI, 2009, 'Not all hERG pore domain mutations have a severe phenotype: G584S has an inactivation gating defect with mild phenotype compared to G572S, which has a dominant negative trafficking defect and a severe phenotype', Journal of Cardiovascular Electrophysiology, vol. 20, pp. 923 - 930, http://dx.doi.org/10.1111/j.1540-8167.2009.01468.x

Jackson CJ; Cooper A; Smillie L, 2008, 'A trait conceptualization of reward-reactivity: psychometric properties of the appetitive motivation scale (AMS)', Journal of Individual Differences, vol. 29, pp. 168 - 180, http://dx.doi.org/10.1027/1614-0001.29.3.168

Kincaid M; Cooper A, 2007, 'ERADicate ER stress or die trying', Antioxidants and Redox Signaling, vol. 9, pp. 2373 - 2387, http://dx.doi.org/10.1089/ars.2007.1817

Kincaid M; Cooper A, 2007, 'Misfolded proteins traffic from the endoplasmic reticulum (ER) due to ER export signals', Molecular Biology of the Cell, vol. 18, pp. 455 - 463, http://dx.doi.org/10.1091/mbc.E06-08-0696

Cooper AA; Gitler AD; Cashikar A; Haynes CM; Hill KJ; Bhullar B; Liu K; Xu K; Strathearn KE; Liu F; Cao S; Caldwell KA; Caldwell GA; Marsischky G; Kolodner RD; LaBaer J; Rochet JC; Bonini NM; Lindquist S, 2006, 'α-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models', Science, vol. 313, pp. 324 - 328, http://dx.doi.org/10.1126/science.1129462

Molero JC; Waring S; Cooper A; Turner N; Laybutt DR; Cooney GJ; James DE, 2006, 'Casitas b-lineage lymphoma-deficient mice are protected against high-fat died-induced obesity and insulin resistance', Diabetes, vol. 55, pp. 708 - 715, http://dx.doi.org/10.2337/diabetes.55.03.06.db05-0312

Haynes CM; Titus EA; Cooper AA, 2004, 'Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death', Molecular Cell, vol. 15, pp. 767 - 776, http://dx.doi.org/10.1016/j.molcel.2004.08.025

Haynes CM; Caldwell S; Cooper AA, 2002, 'An HRD/DER-independent er quality control mechanism involves Rsp5p-dependent ubiquitination and ER-Golgi transport', Journal of Cell Biology, vol. 158, pp. 91 - 101, http://dx.doi.org/10.1083/jcb.200201053

Caldwell SR; Hill KJ; Cooper AA, 2001, 'Degradation of Endoplasmic Reticulum (ER) Quality Control Substrates Requires Transport between the ER and Golgi', Journal of Biological Chemistry, vol. 276, pp. 23296 - 23303, http://dx.doi.org/10.1074/jbc.M102962200

Hill K; Cooper AA, 2000, 'Degradation of unassembled Vph1p reveals novel aspects of the yeast ER quality control system', EMBO Journal, vol. 19, pp. 550 - 561, http://dx.doi.org/10.1093/emboj/19.4.550

Cooper AA; Stevens TH, 1996, 'Vps10p cycles between the late-Golgi and prevacuolar compartments in its function as the sorting receptor for multiple yeast vacuolar hydrolases', Journal of Cell Biology, vol. 133, pp. 529 - 541, http://dx.doi.org/10.1083/jcb.133.3.529

Cooper AA; Stevens TH, 1995, 'Protein splicing: self-splicing of genetically mobile elements at the protein level', Trends in Biochemical Sciences, vol. 20, pp. 351 - 356, http://dx.doi.org/10.1016/S0968-0004(00)89075-1

Piper RC; Cooper AA; Yang H; Stevens TH, 1995, 'VPS27 controls vacuolar and endocytic traffic through a prevacuolar compartment in Saccharomyces cerevisiae', Journal of Cell Biology, vol. 131, pp. 603 - 617, http://dx.doi.org/10.1083/jcb.131.3.603

Cooper AA; Chen YJ; Lindorfer MA; Stevens TH, 1993, 'Protein splicing of the yeast TFP1 intervening protein sequence: A model for self-excision', EMBO Journal, vol. 12, pp. 2575 - 2583, http://dx.doi.org/10.1002/j.1460-2075.1993.tb05913.x

Cooper AA; Stevens TMH, 1993, 'Protein splicing: Excision of intervening sequences at the protein level', BioEssays, vol. 15, pp. 667 - 674, http://dx.doi.org/10.1002/bies.950151006

Cooper A; Bussey H, 1992, 'Yeast Kex1p is a Golgi-associated membrane protein: Deletions in a cytoplasmic targeting domain result in mislocalization to the vacuolar membrane', Journal of Cell Biology, vol. 119, pp. 1459 - 1468, http://dx.doi.org/10.1083/jcb.119.6.1459

Thomas L; Cooper A; Bussey H; Thomas G, 1990, 'Yeast KEX1 protease cleaves a prohormone processing intermediate in mammalian cells', Journal of Biological Chemistry, vol. 265, pp. 10821 - 10824

Cooper A; Bussey H, 1989, 'Characterization of the yeast KEX1 gene product: a carboxypeptidase involved in processing secreted precursor proteins.', Molecular and cellular biology, vol. 9, pp. 2706 - 2714, http://dx.doi.org/10.1128/MCB.9.6.2706

Barclay GA; Cooper A, 1965, '685. The crystal structure of copper(II) ethyl acetoacetate', Journal of the Chemical Society (Resumed), pp. 3746 - 3751, http://dx.doi.org/10.1039/JR9650003746

Farrow SL; Schierding W; Gokuladhas S; Golovina E; Fadason T; Cooper AA; O’Sullivan JM, 2021, Establishing gene regulatory networks from Parkinson’s disease risk loci, http://dx.doi.org/10.1101/2021.04.08.439080

Ho D; Schierding W; Farrow S; Cooper AA; Kempa-Liehr AW; O’Sullivan JM, 2021, Machine learning identifies six genetic variants and alterations in the Heart Atrial Appendage as key contributors to PD risk predictivity, http://dx.doi.org/10.1101/2021.06.29.21259734

Lau D; Magnan C; Hill K; Cooper A; Gambin Y; Sierecki E, 2021, Single molecule fingerprinting reveals different amplification properties of α-synuclein oligomers and preformed fibrils in seeding assay, http://dx.doi.org/10.1101/2021.08.09.455607

Fadason T; Gokuladhas S; Golovina E; Ho D; Farrow S; Nyaga D; Pan H; Karnani N; Wong C; Cooper A; Schierding W; O’Sullivan JM, 2020, A transcription regulatory network within the ACE2 locus may promote a pro-viral environment for SARS-CoV-2 by modulating expression of host factors, http://dx.doi.org/10.1101/2020.04.14.042002

Dong X; Liao Z; Gritsch D; Hadzhiev Y; Bai Y; Locascio JJ; Guennewig B; Liu G; Blauwendraat C; Wang T; Adler CH; Hedreen JC; Faull RLM; Frosch MP; Nelson PT; Rizzu P; Cooper AA; Heutink P; Beach TG; Mattick JS; Müller F; Scherzer CR, 2019, Erratum to: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease (Nature Neuroscience, (2018), 21, 10, (1482-1492), 10.1038/s41593-018-0223-0), United States, http://dx.doi.org/10.1038/s41593-018-0277-z

Guennewig B; Davies Z; Pinese M; Cooper AA, 2017, blkbox: Integration of multiple machine learning approaches to identify disease biomarkers, http://dx.doi.org/10.1101/123430